RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target

Agios Pharmaceuticals, Inc. +4.53%

Agios Pharmaceuticals, Inc.

AGIO

61.64

+4.53%

RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ: AGIO) with a Outperform and maintains $55 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via